

## State of Oklahoma SoonerCare

## Anktiva® (nogapendekin alfa inbakicept-pmln) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
□Physician billing (HCPCS	S code:) □Pharn	nacy billing (NDC:)
Dose:	Regimen:	Start Date (or date of next dose):
Billing Provider Information		
Provider NPI: Provider Name:		
Provider Phone:	Provide	r Fax:
Prescriber Information		
Prescriber NPI:	Prescriber Nam	e:
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
<ul> <li>A. Does member have</li> <li>B. Is cancer unresponsed</li> <li>C. Will Anktiva be used</li> <li>If diagnosis is not list</li> </ul>	nsive to initial Bacillus Calmette-C sed in conjunction with BCG? Yes	gnosis:
For Continued Authoriza	tion:	
<ul> <li>a. If yes, is the current rest</li> <li>b. If no, is the current rest</li> <li>3. Does member have any example.</li> <li>4. Has member experienced</li> <li>a. If yes, please specify</li> </ul>	omplete response to induction dos equest for maintenance dosing? Y quest for a second induction cours evidence of disease recurrence or d adverse drug reactions related to adverse reactions:	/es No
Dungarihan Ciamatuma		Deter
	tmont is modically necessary and	Date: all information is true and correct to the best of my
knowledge. Failure to complete	t <b>ment is medically necessary and</b> this form in full will result in processi	an information is true and correct to the best of my ng delays.

## PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 268 5/15/2024